<DOC>
	<DOCNO>NCT02991118</DOCNO>
	<brief_summary>The purpose study see bemedoic acid ( ETC-1002 ) effective versus placebo patient high cardiovascular risk elevate LDL cholesterol adequately control current therapy .</brief_summary>
	<brief_title>Evaluation Long-Term Efficacy Bempedoic Acid ( ETC-1002 ) Patients With Hyperlipidemia High Cardiovascular Risk</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Fasting LDLC ≥100 mg/dL High cardiovascular risk ( diagnosis HeFH and/or ASCVD ) Be maximally tolerate lipidmodifying therapy Total fasting triglyceride ≥500 mg/dL Renal dysfunction nephrotic syndrome history nephritis Body Mass Index ( BMI ) ≥50kg/m2 Significant cardiovascular disease cardiovascular event past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>hyperlipidemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>familial hypercholesterolemia</keyword>
	<keyword>atherosclerotic cardiovascular disease</keyword>
	<keyword>ASCVD</keyword>
	<keyword>HeFH</keyword>
	<keyword>LDL</keyword>
</DOC>